RUNX3
Basics
Aliases:
This biomarker is also known as:- PEBP2A3,
- CBFA3,
- CBF-alpha-3,
- PEA2-alpha C,
- Polyomavirus enhancer-binding protein 2 alpha C subunit,
- Oncogene AML-2,
- Core-binding factor subunit alpha-3,
- Runt-related transcription factor 3,
- PEBP2-alpha C,
- SL3/AKV core-binding factor alpha C subunit,
- AML2,
- Acute myeloid leukemia 2 protein,
- SL3-3 enhancer factor 1 alpha C subunit,
Description…
RUNX3 is a member of the runt domain-containing family of transcription factors. A heterodimer of this protein and a beta subunit forms a complex that binds to the core DNA sequence 5'-PYGPYGGT-3' found in a number of enhancers and promoters, and can either activate or suppress transcription. It also interacts with other transcription factors. It functions as a tumor suppressor, and the gene is frequently deleted or transcriptionally silenced in cancer. Multiple transcript variants encoding different isoforms have been found for this gene.
Attributes
| QA State: | Accepted |
|---|---|
| Type: | Genomic |
| Short Name: |
Organs
The following organs have data associated with this biomarker…
Esophagus
Attributes
| Phase: | Two |
|---|---|
| QA State: | Accepted |
Overview
Esophageal adenocarcinoma risk in Barrett's esophagus is increased 30- to 125- fold versus the general population. Among all Barrett's esophagus patients neoplastic progression occurs only once per 200 patient-years. Molecular markers (individual or in panel) would be useful to risk-stratify patients for more efficient surveillance endoscopy and to improve the early detection of progression.
Performance Comment
p16, RUNX3, and TMEFF2 (HPP1) display increasing methylation frequencies in Barrett's esophagus versus esophageal adenocarcinoma. These markers are being further investigated for potential utility in screening Barrett's patients likely to develop esophageal adenocarcinoma.
Supporting Study Data
The following studies/protocols provide evidence supporting RUNX3 indications for the Esophagus…
Barrett's Esophagus Methylation Profiles
We propose a nested case-control study of biomarkers in the setting of BE. By bringing together research institutions with large populations of patients with BE, we will perform a multi-center study of FISH and hypermethylation markers as possible prognostic factors in BE. The centers will select from their cohorts who have progressed to HGD or to adenocarcinoma of the esophagus ("progressors"), and who also donated samples prior to the development of cancer, when their histology was felt to be benign. These subjects will be compared to individuals who have been under endoscopic surveillance, but who have not progressed to HGD or EAC ("non-progressors"). Using this approach, we hope to identify promising markers for risk stratification in BE. We expect to be able to make successful application for a prospective study of markers identified in this case-control study.
View more about this studyBiomarker Characteristics Summary
| Notes | Sensitivity | Specificity | Prevalence | NPV | PPV | Specific Assay Type |
|---|---|---|---|---|---|---|
| Assessment of the classification accuracy of a single marker using ROC curve analyses show AUC for HPP1, p16, and RUNX3 are all significantly greater than 0.50. For RUNX3, AUC (95% confidence interval) was 0.671 (0.586, 0.756). | 0.0 | 0.0 | 0.0 |
Decision Rule
PMID:15824739
Additional Study-Specific Protocols
Study-Specific Publications
- A multicenter, double-blinded validation study of methylation biomarkers for progression prediction in Barrett's esophagus.
- Inactivation of p16, RUNX3, and HPP1 occurs early in Barrett's-associated neoplastic progression and predicts progression risk.
Study-Specific Resources
No study-specific resources defined.
Organ-Specific Protocols
No organ-specific protocols defined.
Organ-Specific Publications
No organ-specific publications defined.
Organ-Specific Resources
No organ-specific resources defined.
Lung
Attributes
| Phase: | One |
|---|---|
| QA State: | Under Review |
Overview
Performance Comment
Supporting Study Data
The following studies/protocols provide evidence supporting RUNX3 indications for the Lung…
No supporting studies or protocols found.
Organ-Specific Protocols
No organ-specific protocols defined.
Organ-Specific Publications
No organ-specific publications defined.
Organ-Specific Resources
No organ-specific resources defined.
Studies
No associated studies or protocols found.
Publications
- The State of Molecular Biomarkers for the Early Detection of Lung Cancer.
- DNA methylation in tumor and matched normal tissues from non-small cell lung cancer patients.
- Promoter hypermethylation of CDH13 is a common, early event in human esophageal adenocarcinogenesis and correlates with clinical risk factors.
- A multicenter, double-blinded validation study of methylation biomarkers for progression prediction in Barrett's esophagus.
- Three-tiered risk stratification model to predict progression in Barrett's esophagus using epigenetic and clinical features.
- Similarity of aberrant DNA methylation in Barrett's esophagus and esophageal adenocarcinoma.
- Inactivation of p16, RUNX3, and HPP1 occurs early in Barrett's-associated neoplastic progression and predicts progression risk.
